Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare leader formed through the merger of Upjohn and Mylan, delivering essential medicines across 165+ countries. This page provides centralized access to official corporate announcements and market-moving developments.
Investors and analysts will find timely updates including earnings reports, regulatory milestones, and strategic partnerships. Track the company’s progress in generic pharmaceuticals, biosimilars, and therapeutic innovations through verified press releases.
Our curated news feed serves as a reliable resource for understanding Viatris’ operational decisions, product pipeline advancements, and global healthcare initiatives. Bookmark this page to stay informed about one of the pharmaceutical industry’s most diversified companies.
Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. announced the FDA approval of Semglee® (insulin glargine-yfgn injection) as the first interchangeable biosimilar under the 351(k) pathway. This approval allows Semglee to be substituted for Lantus® at pharmacies and is expected to enhance access to diabetes treatment. The companies will launch Semglee by the end of the year and may enjoy 12 months of exclusivity before competing biosimilars can enter the market. This significant milestone reflects Viatris’ scientific capabilities and commitment to increasing patient access to complex treatments.
Viatris (NASDAQ: VTRS) announced that the U.S. District Court for Kansas dismissed a lawsuit filed by KPH Healthcare Services, asserting claims against Mylan and Pfizer over EpiPen products. The court ruled that KPH lacked legal standing, allowing the case to be dismissed entirely, with a possibility for KPH to file a limited amended complaint within 30 days. Viatris expressed satisfaction with the ruling, emphasizing its commitment to legal compliance and willingness to defend against future proceedings.
Viatris Inc. (NASDAQ: VTRS) will announce its second quarter 2021 financial results on August 9, before the U.S. market opens. A webcast featuring CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will be held at 10 a.m. ET the same day. Investors can listen to the call live via the company's investor website or by phone. Established in November 2020, Viatris focuses on providing access to medicines and healthcare solutions globally, maintaining a portfolio of over 1,400 approved molecules.
Viatris (NASDAQ: VTRS) will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 10:30 a.m. ET. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will discuss the company and address queries. Interested individuals can access the live webcast at investor.viatris.com, with an archived version available later. Viatris aims to empower global health through access to over 1,400 medicines and operates in 165 countries.
Viatris Inc. (VTRS) reported Q1 2021 financial results with total revenue at $4.4 billion, reflecting a 70% increase year-over-year. The company faced a U.S. GAAP net loss of $1.0 billion, while adjusted EBITDA stood at $1.6 billion. Free cash flow reached $799 million. The Board declared a quarterly dividend of $0.11 per share, payable June 26, 2021. Viatris anticipates achieving approximately $500 million in synergies and has generated $163 million from new product revenue, reiterating its positive outlook for the year.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 9:10 a.m. ET. CEO Michael Goettler and CFO Sanjeev Narula will discuss the company and answer questions. A live webcast will be available at investor.viatris.com, with an archived version accessible later. Formed in November 2020 from Mylan and Pfizer's Upjohn business, Viatris serves over 165 countries and offers a diverse portfolio of over 1,400 approved medicines.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the BofA Securities 2021 Health Care Conference on May 11, 2021, at 8 a.m. ET. President Rajiv Malik and CFO Sanjeev Narula will address questions regarding the company. Interested parties can access a live webcast at investor.viatris.com, with an archived version available afterward. Viatris, formed in November 2020, aims to provide global access to a diverse portfolio of over 1,400 medicines targeting various health conditions, supporting sustainable healthcare.
Viatris Inc. (NASDAQ: VTRS) will release its first quarter 2021 financial results on May 10, 2021, prior to the U.S. market opening. A webcast will follow at 10 a.m. ET to discuss these results, accessible at investor.viatris.com or via phone at 855.493.3607. Viatris formed in November 2020, merging Mylan and Pfizer's Upjohn. The company aims to improve global health access with a portfolio of over 1,400 approved molecules and operates in over 165 countries.
On March 8, 2021, Viatris (NASDAQ: VTRS) and Kindeva Drug Delivery announced the FDA granted tentative approval for the first generic version of Symbicort, budesonide/formoterol fumarate dihydrate. This approval, however, comes amid ongoing patent litigation with AstraZeneca, preventing immediate commercial launch. Despite significant U.S. sales of Symbicort, Viatris has not projected any revenue from this product for 2021. This milestone reflects the partnership's strength and Viatris’ commitment to advancing access to respiratory treatments.
FAQ
What is the current stock price of Viatris Ord Shs (VTRS)?
What is the market cap of Viatris Ord Shs (VTRS)?
